Trial Profile

Phase I clinical study of TRG035

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 17 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Oct 2022 New trial record
11 Oct 2022 According to a WuXi Biologics media release, WuXi Biologics and Toregem Biopharma have signed a Memorandum of Understanding (MOU) to form a strategic partnership in the development of TRG035. WuXi Biologics will support Toregem BioPharma on the TRG035 for its Investigational New Drug (IND) application.
11 Oct 2022 According to a WuXi Biologics media release, the company expect to initiate this trial in early 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com